The country’s largest drug distributor, like several of its competitors, remains under fire for its alleged role in America’s destructive opioid epidemic, as plaintiffs and prosecutors accuse it of hiding flaws in its supply chain that made it too easy for doctors to overprescribe and patients to abuse the drugs. In part as a result of a recent settlement with several states, McKesson reported a $4.5 billion loss for the fiscal year that ended in March 2021. After taking charge as a CDC-appointed centralized distributor for COVID vaccines in the U.S., McKesson distributed about 246 million doses as of December 2021. McKesson’s oncology technology business, Ontada, joined MYLUNG to advance precision medicine for lung cancer patients.
Timothy D. EasleyAFP/Getty Images
Company Information
As of 8/3/2022
Country
U.S.
Headquarters
Irving, Texas
Industry
Wholesalers: Health Care
CEO
Brian S. Tyler
Website
Company Type
Public
Ticker
MCK
Revenues ($M)
$263,966
Profits ($M)
$1,114
Market Value ($M)
$47,377
Employees
66,500
Figures are for fiscal year ended March 31, 2022. Market value as of July 19, 2022.
Key Financials (Last Fiscal Year)
$ millions
% change
Revenues ($M)
$238,228
3.1%
Profits ($M)
$-4,539
-604.3%
Assets ($M)
$65,015
-
Total Stockholder Equity ($M)
$-21
-
Profit Ratios
Profit as % of Revenues
-1.9%
Profits as % of Assets
-7%
Profits as % of Stockholder Equity
-
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
-28
EPS % Change (from 2020)
-670.9%
EPS % Change (5 year annual rate)
-
EPS % Change (10 year annual rate)
-
Total Return
Total Return to Investors (2021)
44.3%
Total Return to Investors (5 year, annualized)
13.3%
Total Return to Investors (10 year, annualized)
13.3%
McKesson Rank History
Historical Data
| Year | Revenues ($M) | Profits ($M) | Assets ($M) | Total Stockholder Equity ($M) |
|---|---|---|---|---|
| 2021 | $231,0517.8% | $9002547.1% | $61,247 | $5,092 |
| 2020 | $214,3192.9% | $34-49.3% | $59,672 | $8,094 |
| 2019 | $208,3574.9% | $67-98.7% | $60,381 | $9,804 |
| 2018 | $198,5333.1% | $5,070124.5% | $60,969 | $11,095 |
| 2017 | $192,4876.2% | $2,25853% | $56,563 | $8,924 |
SHOW MORE
Lists ranking McKesson
Latest news for McKesson
- Success
How the top 10 Fortune 500 companies are bringing workers back to the officeAugust 14, 2022, 1:00 PM UTC - Health
Johnson & Johnson, drug distributors reach $26 billion settlement with states over opioidsJuly 21, 2021, 7:25 PM UTC - Health
4 Drug Giants Reach $260 Million Settlement in Ohio Opioid Case. What Happens Next?October 21, 2019, 5:27 PM UTC
